If you are:
FDB Contraindicated or Not Recommended: FDA C; INSUFFICIENT HUMAN DATA. RISK OF MALFORMATIONS. AVOID IN 1ST TRIMESTER
Only When Necessary: NEONATAL WITHDRAWAL/RESP.DEPRESS. W/CHRONIC OR HIGH DOSE; SMALL TERATOGENIC RISK
FDB Contraindicated or Not Recommended: NO FDA CATEGORY; NOT RECOMMENDED ESPECIALLY IN 3RD TRIMESTER OR NEAR TERM
Precaution: LIMITED DATA SUGGEST INFANT SEDATION MAY BE GREATER WITH EXPOSURE
Precaution: CNS/RESPIRATORY DEPRESSION,APNEA POSSIBLE;CAUTION W/ FAST CYP2D6 METABOLIZER
Absolute Contraindication: ONE REPORT OF METABOLIC ACIDOSIS; RISK OF REYE'S SYND IN VIRAL ILLNESS.
An adult over 60:
management or monitoring precaution: Neuro/Psych-Generally not recommended due to risks for confusion, cognitive impairment and sedation leading to increased falls.
management or monitoring precaution: Pulmonary-Life threatening respiratory depression is more likely to occur with high doses, SR products, cachexia, or debilitation due to altered pharmacokinetics with poor fat stores, muscle wasting, or altered clearance. Monitor closely at initiation and with dose titration. Neuro/Psych-Risk for increased confusion and delirium. May increase fall risk. Avoid treatment with 3 or more CNS active drugs. Gastrointestinal-Constipation risk. Urogenital-Urinary retention risk.
Giving CARISOPRODOL COMPOUND-CODEINE to a child under 12:
management or monitoring precaution: Safety and efficacy not established in children less than 16 years.
Severe Precaution: Contraindicated post-surgical tonsillectomy or adenoidectomy age < 18 years. Contraindicated for any indication age < 12 years per Health Canada. Respiratory depression and death reported in CYP2D6 ultra-rapid metabolizer patients post tonsillectomy or adenoidectomy. Specific CYP2D6 genotypes convert codeine into morphine more rapidly and achieve high levels of morphine. Increased risk of CNS and respiratory depression especially with asthma or other underlying breathing problem.
Severe Precaution: Contraindicated for pain management post-surgical tonsillectomy and or adenoidectomy. Respiratory depression and death reported in CYP2D6 ultra-rapid metabolizer patients post tonsillectomy or adenoidectomy. Specific CYP2D6 genotypes convert codeine into morphine more rapidly and achieve higher levels of morphine even with standard dosing. Slow or difficult breathing risk in patients with asthma or other underlying breathing problem.
Severe Precaution: Reye syndrome risk with viral illness, fever, and/or flu symptoms.